Regeneron Secures Sanofi-Aventis Antibody Funding Through 2017
Building on an existing partnership, Regeneron may receive as much as $1.3 billion from Sanofi-Aventis through 2017 with no obligation to repay.
Building on an existing partnership, Regeneron may receive as much as $1.3 billion from Sanofi-Aventis through 2017 with no obligation to repay.